{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:58:39Z","timestamp":1781240319909,"version":"3.54.1"},"reference-count":194,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among women worldwide. It is a highly heterogeneous disease that can be divided into different molecular subtypes, which differ in morphology, prognosis, and treatment response. While metabolic reprogramming is known to support tumor growth and survival, the specific role of L-arginine metabolism in breast cancer is not completely understood. L-Arginine is a semi-essential amino acid, it is involved in key pathways regulating cell proliferation, immune response, and protein metabolism. Dysregulation of L-arginine-related enzymes, such as arginases and nitric oxide synthases, can influence tumor growth, metabolic signaling, and the interaction between cancer and immune cells. Therapeutic targeting of L-arginine metabolism has been explored by three main approaches: L-arginine starvation, L-arginine supplementation, and enzyme inhibition. However, results have remained inconsistent, possibly due to differences in metabolic adaptations across molecular breast cancer subtypes. This review provides an overview of current knowledge on L-arginine metabolism in breast cancer, including metabolic reprogramming, subtype-specific regulation, and therapeutic opportunities. It also discusses challenges and highlights the need for further research to define subtype-specific regulation of L-arginine metabolism.<\/jats:p>","DOI":"10.3389\/fonc.2026.1844871","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:43:18Z","timestamp":1781239398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["L-arginine metabolism in breast cancer: mechanisms and therapeutic targets"],"prefix":"10.3389","volume":"16","author":[{"given":"Antonia","family":"R\u00f6glin","sequence":"first","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"B\u00f6ger","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Hannemann","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7687851","article-title":"Metabolic footprints and molecular subtypes in breast cancer","volume":"2017","author":"Cappelletti","year":"2017","journal-title":"Dis Markers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"S\u00f8rlie","year":"2003","journal-title":"Proc Natl Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-7-96","article-title":"The molecular portraits of breast tumors are conserved across microarray platforms","volume":"7","author":"Hu","year":"2006","journal-title":"BMC Genomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/JAMA.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet (London England)"},{"key":"B10","unstructured":"Cancer stat facts: female breast cancer subtypes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.2009-0078","article-title":"Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy","volume":"14","author":"Guarneri","year":"2009","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJN309","article-title":"Outcome prediction for estrogen receptor\u2013positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"JNCI J Natl Cancer Inst"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/jca.18457","article-title":"Breast cancer cell line classification and its relevance with breast tumor subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3892\/or.12.4.701","article-title":"Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes","volume":"12","author":"Lacroix","year":"2004","journal-title":"Oncol Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2970","article-title":"The prognostic implication of the basal-like (Cyclin Ehigh\/p27low\/p53+\/Glomeruloid-Microvascular-Proliferation+) phenotype of BRCA1-related breast cancer","volume":"64","author":"Foulkes","year":"2004","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2009.06.027","article-title":"Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases","volume":"45","author":"Heitz","year":"2009","journal-title":"Eur J Cancer"},{"key":"B20","article-title":"Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches","volume":"12","author":"Tufail","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15041320","article-title":"Targeted therapy and mechanisms of drug resistance in breast cancer","volume":"15","author":"Kinnel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/S13058-018-1075-Y","article-title":"Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics","volume":"20","author":"Kus","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3360001","article-title":"Arginine metabolism: nitric oxide and beyond","volume":"336","author":"Wu","year":"1998","journal-title":"Biochem J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.130.3373.432","article-title":"Amino acid metabolism in mammalian cell cultures","volume":"130","author":"Eagle","year":"1959","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV.GE.20.120186.002243","article-title":"Mammalian urea cycle enzymes","volume":"20","author":"Jackson","year":"1986","journal-title":"Annu Rev Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/0148607186010002227","article-title":"Arginine: biochemistry, physiology, and therapeutic implications","volume":"10","author":"Barbul","year":"1986","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1126\/science.86.2231.298","article-title":"The nutritive significance of the amino acids and certain related compounds","volume":"86","author":"Rose","year":"1937","journal-title":"Science (80-)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.23.6.1121","article-title":"Nitric oxide synthase isozymes characterization, purification, molecular cloning, and functions","volume":"23","author":"F\u00f6rstermann","year":"1994","journal-title":"Hypertension"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-819460-7.00128-6","article-title":"Regulation: Transcriptional and post-translational regulation of the dimethylarginines ADMA and SDMA and their impact on the L-arginine - Nitric oxide pathway","volume-title":"Encycl. Biol. Chem","author":"Hannemann","year":"2021"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1152\/PHYSREV.00037.2016","article-title":"Arginase: a multifaceted enzyme important in health and disease","volume":"98","author":"Caldwell","year":"2018","journal-title":"Physiol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2004.07.010","article-title":"The role of early expression of inducible nitric oxide synthase in human breast cancer","volume":"41","author":"Loibl","year":"2005","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1172\/JCI42059","article-title":"Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients","volume":"120","author":"Glynn","year":"2010","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000030114","article-title":"Endothelial nitric oxide synthase: correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer","volume":"21","author":"Martin","year":"2000","journal-title":"Tumor Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806216","article-title":"Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines","volume":"40","author":"Zeillinger","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prp.2005.10.003","article-title":"Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7-estrogen has an influence on e-NOS, but not on i-NOS","volume":"202","author":"Loibl","year":"2006","journal-title":"Pathol Pract"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.409","article-title":"Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation","volume":"70","author":"Jenkins","year":"1994","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1152\/AJPCELL.1982.243.5.C212","article-title":"Polyamine metabolism and function","volume":"12","author":"Pegg","year":"1982","journal-title":"Am J Physiol Cell Physiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/0305-0491(95)02138-8","article-title":"Comparative properties of arginases","volume":"114","author":"Jenkinson","year":"1996","journal-title":"Comp Biochem Physiol Part B Biochem Mol Biol"},{"key":"B39","article-title":"Arginase activity in human breast cancer cell lines: N-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells","volume":"60","author":"Singh","year":"2000","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.26.16624","article-title":"Argininosuccinate synthetase overexpression in vascular smooth muscle cells potentiates immunostimulant-induced NO production","volume":"272","author":"Xie","year":"1997","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3892\/OR.2015.4280\/HTML","article-title":"Argininosuccinate lyase is a potential therapeutic target in breast cancer","volume":"34","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2005.01.009","article-title":"IL-1b stimulates argininosuccinate synthetase gene expression through NF-jB in Caco-2 cells","volume":"87","author":"Brasse-Lagnel","year":"2005","journal-title":"Biochimie"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00864","article-title":"Reconstitution of T cell proliferation under arginine limitation: Activated human T cells take up citrulline via L-Type amino acid transporter 1 and use it to regenerate arginine after induction of argininosuccinate synthase expression","volume":"8","author":"Werner","year":"2017","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-03066-6","article-title":"Structural basis for amino acid transport by the CAT family of SLC7 transporters","volume":"9","author":"Jungnickel","year":"2018","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c170041","article-title":"Amino acid transport across the mammalian intestine","volume":"9","author":"Br\u00f6er","year":"2019","journal-title":"Compr Physiol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123975","article-title":"Transport  of L-arginine related cardiovascular risk markers","volume":"9","author":"Banjarnahor","year":"2020","journal-title":"J Clin Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1074\/JBC.274.34.23740","article-title":"Cloning and functional expression of a human Na+and Cl--dependent neutral and cationic amino acid transporter B0+","volume":"274","author":"Sloan","year":"1999","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1242\/JEB.196.1.15","article-title":"Structure, function and evolution of solute transporters in prokaryotes and eukaryotes","volume":"196","author":"Hediger","year":"1994","journal-title":"J Exp Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.65.070196.001513","article-title":"Molecular biology of mammalian amino acid transporters","volume":"65","author":"Malandro","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1998.78.4.969","article-title":"Molecular biology of mammalian plasma membrane amino acid transporters","volume":"78","author":"Palacin","year":"1998","journal-title":"Physiol Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/0115748928279007231130070056","article-title":"Increased SLC7A3 expression inhibits tumor cell proliferation and predicts a favorable prognosis in breast cancer","volume":"20","author":"He","year":"2024","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"B52","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00726-013-1556-3","article-title":"Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1)","volume":"45","author":"Strobel","year":"2013","journal-title":"Amino Acids"},{"key":"B53","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.yjmcc.2012.06.002","article-title":"Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1)","volume":"53","author":"Strobel","year":"2012","journal-title":"J Mol Cell Cardiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1152\/AJPCELL.2001.281.4.C1077","article-title":"Function and structure of heterodimeric amino acid transporters","volume":"281","author":"Wagner","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1113\/JPHYSIOL.1992.SP019275","article-title":"Identification of a new transport system (y+L) in human erythrocytes that recognizes lysine and leucine with high affinity","volume":"454","author":"Dev\u00e9s","year":"1992","journal-title":"J Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-290","article-title":"Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes","volume":"11","author":"Poschke","year":"2013","journal-title":"J Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1042\/bj3490787","article-title":"The heterodimeric amino acid transporter 4F2hc\/y+LAT2 mediates arginine efflux in exchange with glutamine","volume":"349","author":"Br\u00f6er","year":"2000","journal-title":"Biochem J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.229518","article-title":"SLC6A14 (ATB 0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer","volume":"286","author":"Karunakaran","year":"2011","journal-title":"J Biol Chem"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2009.07.016","article-title":"Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production","volume":"60","author":"Pope","year":"2009","journal-title":"Pharmacol Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2017.05.019","article-title":"Arginine-nitric oxide metabolites and cardiac dysfunction in patients with breast cancer","volume":"70","author":"Finkelman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: Who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Cell Press"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0092-8674(01)00423-8","article-title":"State of the Arg: Protein methylation at arginine comes of age","volume":"106","author":"McBride","year":"2001","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.1.124-131.2005","article-title":"Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression","volume":"79","author":"Boulanger","year":"2005","journal-title":"J Virol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.04.003","article-title":"Arginine methylation: An emerging regulator of protein function","volume":"18","author":"Bedford","year":"2005","journal-title":"Mol Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS25168854","article-title":"Role of PRMT1 and PRMT5 in breast cancer","volume":"25","author":"Martinez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS26167899","article-title":"Role of transport proteins for the renal handling of L-arginine and related derivatives","volume":"26","author":"Scherpinski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.254078","article-title":"Alanine-glyoxylate aminotransferase-2 metabolizes endogenous methylarginines, regulates NO, and controls blood pressure","volume":"32","author":"Caplin","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00998.2007","article-title":"Dimethylarginine dimethylaminohydrolase (DDAH): Expression, regulation, and function in the cardiovascular and renal systems","volume":"293","author":"Palm","year":"2007","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000128897.54893.26","article-title":"Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway","volume":"24","author":"Vallance","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/NM1543","article-title":"Disruption of methylarginine metabolism impairs vascular homeostasis","volume":"13","author":"Leiper","year":"2007","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M603606200","article-title":"Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function","volume":"282","author":"Cardounel","year":"2006","journal-title":"J Biol Chem"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.03.015","article-title":"Asymmetric and symmetric dimethylarginine as markers of endothelial dysfunction in cerebrovascular disease: A prospective study nutrition, metabolism & cardiovascular diseases","volume":"34","author":"Bima","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000101924.04515.2E","article-title":"Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence","volume":"108","author":"Dayoub","year":"2003","journal-title":"Circulation"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS141224412","article-title":"Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease","volume":"14","author":"Franceschelli","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90865-Z","article-title":"Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure","volume":"339","author":"Leone","year":"1992","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-9-5","article-title":"From arginine methylation to ADMA: A novel mechanism with therapeutic potential in chronic lung diseases","volume":"9","author":"Zakrzewicz","year":"2009","journal-title":"BMC Pulm Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(03)00500-5","article-title":"The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor","volume":"59","author":"B\u00f6ger","year":"2003","journal-title":"Cardiovasc Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/07853890500472151","article-title":"Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond","volume":"38","author":"B\u00f6ger","year":"2006","journal-title":"Ann Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/137.6.1602s","article-title":"Arginine metabolism: Boundaries of our knowledge","volume":"137","author":"Morris","year":"2007","journal-title":"J Nutr"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109101","article-title":"Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation","volume":"35","author":"Crump","year":"2021","journal-title":"Cell Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cellimm.2005.01.004","article-title":"Immunology cellular L-arginine modulates CD3 expression and T cell function in activated human T lymphocytes","volume":"232","author":"Zea","year":"2004","journal-title":"Cell Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1042\/CS20040096","article-title":"Tumour cell growth in culture: Dependence on arginine","volume":"107","author":"Caso","year":"2004","journal-title":"Clin Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1126\/SCISIGNAL.2004761","article-title":"Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells","volume":"7","author":"Qiu","year":"2014","journal-title":"Sci Signal"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41540-021-00195-5","article-title":"Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer","volume":"7","author":"Karvelsson","year":"2021","journal-title":"NPJ Syst Biol Appl"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-018-0178-4","article-title":"Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction","volume":"1","author":"Cheng","year":"2018","journal-title":"Commun Biol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.23723","article-title":"Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase","volume":"123","author":"Bowles","year":"2008","journal-title":"Int J Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2826","article-title":"Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism","volume":"69","author":"Norian","year":"2009","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217680","article-title":"The arginine metabolism and its deprivation in cancer therapy","volume":"620","author":"Feng","year":"2025","journal-title":"Cancer Lett"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06672-z","article-title":"ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis","volume":"15","author":"Luo","year":"2024","journal-title":"Cell Death Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22235-8","article-title":"Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor","volume":"12","author":"Zou","year":"2021","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-025-07788-6","article-title":"Invasive lobular carcinoma: Integrated multi-omics analysis reveals silencing of argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance","volume":"16","author":"Gupta","year":"2025","journal-title":"Cell Death Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1049147","article-title":"A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors","volume":"13","author":"Ding","year":"2023","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.celrep.2019.01.059","article-title":"Mapping metabolic events in the cancer cell cycle reveals arginine catabolism in the committed SG 2 M phase","volume":"26","author":"Roci","year":"2019","journal-title":"Cell Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079242","article-title":"Proteomic identification of mitochondrial targets of arginase in human breast cancer","volume":"8","author":"Singh","year":"2013","journal-title":"PloS One"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100636","article-title":"Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression","volume":"7","author":"Giannoudis","year":"2022","journal-title":"Eurpean Soc Med Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8696923","article-title":"The involvement of arginase and nitric oxide synthase in breast cancer development: Arginase and NO synthase as therapeutic targets in cancer","volume":"2018","author":"Avtandilyan","year":"2018","journal-title":"BioMed Res Int"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3156-7","article-title":"Polyamines metabolism and breast cancer: State of the art and perspectives","volume":"148","author":"Cervelli","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/JN\/134.10.2743S","article-title":"Enzymes of arginine metabolism","volume":"134","author":"Morris","year":"2004","journal-title":"J Nutr"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/JN\/137.6.1681S","article-title":"Arginine and immunity","volume":"137","author":"Popovic","year":"2007","journal-title":"J Nutr"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-11-118","article-title":"Nitric oxide and cancer: A review","volume":"11","author":"Korde Choudhari","year":"2013","journal-title":"World J Surg Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3233\/BME-130784","article-title":"A novel liposomal nanomedicine for nitric oxide delivery and breast cancer treatment","volume":"24","author":"Lee","year":"2014","journal-title":"Bio-Med Mater Eng"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005912906436","article-title":"Role of nitric oxide in tumour progression: Lessons from human tumours","volume":"17","author":"Thomsen","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1910","article-title":"The role of nitric oxide in tumour progression","volume":"6","author":"Fukumura","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4623","article-title":"Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: Involvement of mammalian target of rapamycin\/eIF4E pathway","volume":"67","author":"Pervin","year":"2007","journal-title":"Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15430\/JCP.2016.21.1.1","article-title":"The potential role of nitric oxide in halting cancer progression through chemoprevention","volume":"21","author":"Vahora","year":"2016","journal-title":"J Cancer Prev"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.job.2020.12.002","article-title":"Indicators of L-arginine metabolism in saliva: A focus on breast cancer","volume":"63","author":"Bel\u2019skaya","year":"2021","journal-title":"J Oral Biosci"},{"key":"B108","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.imbio.2007.09.008","article-title":"Role of arginine metabolism in immunity and immunopathology","volume":"212","author":"Peranzoni","year":"2008","journal-title":"Immunobiology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J Interf Cytokine Res"},{"key":"B110","volume-title":"The cytokine handbook, Volume 1","author":"Thomson","year":"2003"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1097\/01.NNR.0000280655.58266.6c","article-title":"Cytokine comparisons between women with breast cancer and women with a negative breast biopsy","volume":"57","author":"Lyon","year":"2008","journal-title":"Nurs Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2006.192","article-title":"Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients","volume":"44","author":"Fuksiewicz","year":"2006","journal-title":"Clin Chem Lab Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.12.017","article-title":"Serum cytokine profile in patients with breast cancer","volume":"89","author":"Li","year":"2016","journal-title":"Cytokine"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.11.025","article-title":"Metabolic switch in cancer: Survival of the fittest","volume":"180","author":"Raskov","year":"2023","journal-title":"Eur J Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02187-8","article-title":"Emerging roles of aerobic glycolysis in breast cancer","volume":"22","author":"Wu","year":"2020","journal-title":"Clin Transl O"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/S10549-022-06637-W","article-title":"PIK3CA-mutations in breast cancer","volume":"196","author":"Reinhardt","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13143541","article-title":"Arginine signaling and cancer metabolism","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03828-4","article-title":"Arginine-dependent immune responses","volume":"78","author":"Mart\u00ed","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1186539","article-title":"Crosstalk between arginine, glutamine, and the branched chain amino acid metabolism in the tumor microenvironment","volume":"13","author":"Wetzel","year":"2023","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.20892\/J.ISSN.2095-3941.2025.0202","article-title":"The arginine metabolism battlefield: How metabolite exchange in the tumor microenvironment shapes an immunosuppressive ecosystem","volume":"22","author":"Zhu","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-03446-1","article-title":"Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity","volume":"15","author":"Grzybowski","year":"2025","journal-title":"Sci Rep"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.26508\/LSA.202302339","article-title":"Reprogramming of breast tumor\u2013associated macrophages with modulation of arginine metabolism","volume":"7","author":"Fernando","year":"2024","journal-title":"Life Sci Alliance"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2022.112840","article-title":"Arginase: An emerging and promising therapeutic target for cancer treatment","volume":"149","author":"Niu","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2025.03.015","article-title":"Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion","volume":"43","author":"Zhu","year":"2025","journal-title":"Cancer Cell"},{"key":"B127","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/S40170-025-00384-4","article-title":"Immunogenic shift of arginine metabolism triggers systemic metabolic and immunological reprogramming to suppress HER2\u2009+\u2009breast cancer","volume":"13","author":"Sharma","year":"2025","journal-title":"Cancer Metab"},{"key":"B128","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-025-13908-4","article-title":"L-arginine dependence of breast cancer \u2013 molecular subtypes matter","volume":"25","author":"Hannemann","year":"2025","journal-title":"BMC Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"80568","DOI":"10.18632\/ONCOTARGET.19631","article-title":"Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways","volume":"8","author":"Garrido","year":"2017","journal-title":"Oncotarget"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0527-x","article-title":"Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer","volume":"17","author":"Granados-Principal","year":"2015","journal-title":"Breast Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2016.6813","article-title":"Nitric oxide synthase-2-derived nitric oxide drives multiple pathways of breast cancer progression","volume":"26","author":"Basudhar","year":"2017","journal-title":"Antioxidants 6 Redox Signal"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-022-00313-4","article-title":"Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer","volume":"6","author":"Velenosi","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1152\/ajpendo.90217.2008","article-title":"Spermidine\/spermine-N1-acetyltransferase: A key metabolic regulator","volume":"294","author":"Pegg","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-09-1550","article-title":"An RNAi screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature","volume":"70","author":"Kourtidis","year":"2010","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer","volume":"103","author":"Pan","year":"2024","journal-title":"Madicine"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.08.002","article-title":"A central role for mTOR in lipid homeostasis","volume":"18","author":"Lamming","year":"2013","journal-title":"Cell Metab"},{"key":"B137","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tem.2018.10.006","article-title":"Crosstalk between estrogen signaling and breast cancer metabolism","volume":"30","author":"Kulkoyluoglu-Cotul","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.503","article-title":"Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells","volume":"5","author":"Wang","year":"2014","journal-title":"Cell Death Dis"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3390\/cells15010025","article-title":"Inhibition of tumor microenvironment-driven JAK-STAT signaling enhances response to arginine deprivation therapy in triple-negative breast cancer","volume":"15","author":"Tishler","year":"2025","journal-title":"Cells"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/CAM4.4446","article-title":"Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors","volume":"11","author":"Yao","year":"2022","journal-title":"Cancer Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1177\/0148607197021004215","article-title":"Arginine-enhanced enteral nutrition augments the growth of a nitric oxide-producing tumor","volume":"21","author":"Edwards","year":"1997","journal-title":"J Parenter Enter Nutr"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2376-0","article-title":"L-arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo","volume":"16","author":"Cao","year":"2016","journal-title":"BMC Cancer"},{"key":"B143","article-title":"L-arginine stimulates host defenses in patients with breast cancer","volume":"115","author":"Brittenden","year":"1994","journal-title":"Surgery"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1042\/cs0820413","article-title":"Stimulation of human breast cancers by dietary L-arginine","volume":"82","author":"Park","year":"1992","journal-title":"Clin Sci"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.12.1.221","article-title":"Potentiation of the response to chemotherapy in patients with breast cancer by dietary supplementation with L-arginine: Results of a randomised controlled trial","volume":"12","author":"Heys","year":"1998","journal-title":"Int J Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1002\/JBT.70130","article-title":"Arginase activity inhibition with thymoquinone induces a hybrid type of cell\u2010death in MDA\u2010MB\u2010231 cell line","volume":"39","author":"Bday","year":"2025","journal-title":"J Biochem Mol Toxicol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1316437","article-title":"Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade","volume":"6","author":"Secondini","year":"2017","journal-title":"Oncoimmunology"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104316","article-title":"The potential therapeutic effect of N G-hydroxy-nor-L-arginine in 7,12-dimethylbenz(a)anthracene-induced breast cancer in rats","volume":"111","author":"Avtandilyan","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.01.154","article-title":"Flavone inhibits nitric oxide synthase (NOS) activity, nitric oxide production and protein S-nitrosylation in breast cancer cells","volume":"458","author":"Zhu","year":"2015","journal-title":"Biochem A"},{"key":"B150","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41374-020-00507-z","article-title":"Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells","volume":"101","author":"L\u00f3pez-S\u00e1nchez","year":"2021","journal-title":"Lab Investig"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-022-04489-y","article-title":"Anti-cancer effect of in vivo inhibition of nitric oxide synthase in a rat model of breast cancer","volume":"478","author":"Avtandilyan","year":"2023","journal-title":"Mol Cell Biochem"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.05.027","article-title":"Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase","volume":"459","author":"Flaherty","year":"2019","journal-title":"Cancer Lett"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-54651-x","article-title":"NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression","volume":"15","author":"Reddy","year":"2024","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","first-page":"P5-17","DOI":"10.1158\/1538-7445.SABCS21-P5-17-07","article-title":"Phase 1B\/2 clinical trial targeting nitric oxide in the treatment of chemo-refractory metaplastic triple-negative breast cancer patients","volume":"82","author":"Puri","year":"2022","journal-title":"Cancer Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.ABJ5070","article-title":"A phase 1\/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer","volume":"13","author":"Chung","year":"2021","journal-title":"Sci Transl Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/JCB.23022","article-title":"CAT-1-mediated arginine uptake and regulation of nitric oxide synthases for the survival of human breast cancer cell lines","volume":"112","author":"Abdelmagid","year":"2011","journal-title":"J Cell Biochem"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.012376","article-title":"Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy","volume":"295","author":"Renee Geck","year":"2020","journal-title":"J Biol Chem"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.636373","article-title":"Dual inhibition of ornithine decarboxylase and A1 adenosine receptor efficiently suppresses breast tumor cells","volume":"11","author":"Ma","year":"2021","journal-title":"Front Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3109\/14756366.2014.926342","article-title":"N-\u03c9-chloroacetyl-l-ornithine, a new competitive inhibitor of ornithine decarboxylase, induces selective growth inhibition and cytotoxicity on human cancer cells versus normal cells","volume":"30","author":"Medina-Enr\u00edquez","year":"2015","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000353","article-title":"N-\u03c9-chloroacetyl-L-ornithine has in-vitro activity against cancer cell lines and in-vivo activity against ascitic and solid tumors","volume":"27","author":"Vargas-Ram\u00edrez","year":"2016","journal-title":"Anticancer Drugs"},{"key":"B161","article-title":"Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients","volume":"5","author":"O\u2019Shaughnessy","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.12.117","article-title":"Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro","volume":"111","author":"Hulin","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nat Chem Biol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020306","article-title":"PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer","volume":"14","author":"Suresh","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B165","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12282-017-0790-z","article-title":"The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells","volume":"25","author":"Nakai","year":"2018","journal-title":"Breast Cancer"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02315","article-title":"A CARM1 inhibitor potently suppresses breast cancer both in vitro and in vivo","volume":"67","author":"Peng","year":"2024","journal-title":"J Med Chem"},{"key":"B167","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.1038\/s41598-018-28002-y","article-title":"Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing","volume":"8","author":"Gerhart","year":"2018","journal-title":"Sci Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46495-2","article-title":"PRMT5 is an actionable therapeutic target in CDK4\/6 inhibitor-resistant ER+\/RB-deficient breast cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177350","article-title":"Targeting protein arginine methyltransferases in breast cancer: Promising strategies","volume":"992","author":"Wei","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2019.109210","article-title":"Arginine metabolism and deprivation in cancer therapy","volume":"118","author":"Zou","year":"2019","journal-title":"BioMed Pharmacother"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175830","article-title":"Arginine deprivation as a treatment approach targeting cancer cell metabolism and survival: A review of the literature","volume":"953","author":"Assi","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES28052150","article-title":"Bench-to-bedside studies of arginine deprivation in cancer","volume":"28","author":"Field","year":"2023","journal-title":"Mol"},{"key":"B174","article-title":"PEGylated recombinant human arginase for breast cancer","volume":"25","author":"Leung","year":"2019","journal-title":"Heal Med Res Fund"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3605","article-title":"Activation of Ras\/PI3K\/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells","volume":"72","author":"Tsai","year":"2012","journal-title":"Cancer Res"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950501)75:9<2313::aid-cncr2820750921>3.0.co;2-6","article-title":"Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice","volume":"75","author":"Alagoz","year":"1995","journal-title":"Cancer"},{"key":"B177","first-page":"73","article-title":"Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells","volume":"41","author":"Teicher","year":"1981","journal-title":"Cancer Res"},{"key":"B178","article-title":"Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity","volume":"61","author":"Chang","year":"2001","journal-title":"Cancer Res"},{"key":"B179","unstructured":"First-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 in patients with selected advanced and\/or metastatic solid tumours. Identifier NCT05759923\n          \n          \n          \n          2023"},{"key":"B180","unstructured":"Arginase inhibitor INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced\/metastatic solid tumors identifier NCT02903914\n          \n          \n            \n              Kuriakose\n              E\n            \n            \n              Gogov\n              S\n            \n          \n          \n          2016"},{"key":"B181","unstructured":"A study of INCMGA00012, INCB001158, and the combination in Japanese participants with advanced solid tumors identifier NCT03910530\n          \n          \n            \n              Ueda\n              E\n            \n          \n          \n          2019"},{"key":"B182","unstructured":"A study to evaluate the safety, tolerability, and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in advanced solid tumors identifier NCT03361228\n          \n          \n            \n              Gogov\n              S\n            \n          \n          \n          2018"},{"key":"B183","unstructured":"A phase 1\/2 study of INCB001158 in combination with chemotherapy in subjects with solid tumors identifier NCT03314935\n          \n          \n            \n              Leopold\n              L\n            \n          \n          \n          2017"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1023023","article-title":"Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors \u2013 A phase I trial","volume":"13","author":"Lorentzen","year":"2022","journal-title":"Front Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000249","article-title":"First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours","volume":"3","author":"Naing","year":"2024","journal-title":"BMJ Oncol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3791\/52671","article-title":"Mammosphere formation assay from human breast cancer tissues and cell lines","volume":"2015","author":"Lombardo","year":"2015","journal-title":"J Vis Exp"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.2174\/156652411795678007","article-title":"Mammary development and breast cancer: The role of stem cells","volume":"11","author":"Ercan","year":"2011","journal-title":"Curr Mol Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2016.12.003","article-title":"Nitric oxide-mediated resistance to photodynamic therapy in a human breast tumor xenograft model: Improved outcome with NOS2 inhibitors","volume":"62","author":"Fahey","year":"2016","journal-title":"Nitric Oxide"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14454-1","article-title":"MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1","volume":"7","author":"Hulin","year":"2017","journal-title":"Sci Rep"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1039\/C5OB01843A","article-title":"Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1","volume":"13","author":"Tommasi","year":"2015","journal-title":"Org Biomol Chem"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES21050615","article-title":"Inhibitors of the hydrolytic enzyme dimethylarginine dimethylaminohydrolase (DDAH): Discovery, synthesis and development","volume":"21","author":"Murphy","year":"2016","journal-title":"Mol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1093\/MUTAGE\/GEU039","article-title":"Arginine methyltransferases as novel therapeutic targets for breast cancer","volume":"30","author":"Morettin","year":"2015","journal-title":"Mutagenesis"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1007\/S10637-012-9862-2","article-title":"Phase I\/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma","volume":"31","author":"Ott","year":"2013","journal-title":"Invest New Drugs"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: The ATOMIC-Meso randomized clinical trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844871\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:43:39Z","timestamp":1781239419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844871\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":194,"alternative-id":["10.3389\/fonc.2026.1844871"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1844871","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1844871"}}